Iguana Healthcare Management’s Acceleron Pharma XLRN Stock Holding History

Iguana Healthcare Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-70,000	Closed	-$2.61M	–	79
2017 Q3	$2.61M	Buy	+70,000	New	+$2.43M	1.42%	31
2017 Q1	–	Sell	-60,000	Closed	-$1.53M	–	83
2016 Q4	$1.53M	Sell	60,000 -10,000	-14%	-$317K	0.92%	35
2016 Q3	$2.53M	Buy	70,000 +20,000	+40%	+$663K	0.45%	61
2016 Q2	$1.7M	Sell	50,000 -25,000	-33%	-$813K	0.69%	46
2016 Q1	$1.98M	Sell	75,000 -75,000	-50%	-$2.18M	0.73%	41
2015 Q4	$7.31M	Buy	150,000 +40,000	+36%	+$1.44M	2.41%	11
2015 Q3	$2.74M	Sell	110,000 -40,000	-27%	-$1.2M	1.08%	31
2015 Q2	$4.75M	Sell	150,000 -25,000	-14%	-$807K	1.5%	26
2015 Q1	$6.66M	Sell	175,000 -40,000	-19%	-$1.59M	2.8%	7
2014 Q4	$8.38M	Buy	215,000 +190,000	+760%	+$6.62M	4.05%	6
2014 Q3	$756K	Sell	25,000 -85,000	-77%	-$2.39M	0.4%	56
2014 Q2	$3.74M	Buy	+110,000	New	+$3.68M	1.74%	22

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Iguana Healthcare Management's XLRN Position: Q4 2017 in Review

Iguana Healthcare Management sold out of Acceleron Pharma (XLRN) in Q4 2017, closing a stake of 70,000 shares — an estimated $2.61M sold.

Iguana Healthcare Management first reported a position in XLRN in Q2 2014 and held it in 12 quarters. The position peaked at $8.38M in Q4 2014. 137 funds tracked by Wall St. Rank hold XLRN as of Q4 2017.

Iguana Healthcare Management reported no remaining Acceleron Pharma position as of Q4 2017 after selling out during the quarter.
Iguana Healthcare Management sold 70,000 Acceleron Pharma shares in Q4 2017, an estimated $2.61M.
Iguana Healthcare Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 12 quarters.
Iguana Healthcare Management's Acceleron Pharma position peaked at $8.38M in Q4 2014.
137 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2017.

Based on Iguana Healthcare Management's 13F filing for Q4 2017, filed 14 Feb 2018.